The history of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial introduction generated massive profits, the end of its intellectual property protection opened the door to off-brand alternatives, dramatically diminishing market share. This presents a unique dilemma for firms relying on related blockbuste

The history of Viagra, and its parent company copyright, presents a complex case study for investors. At first a blockbuster drug, producing billions in revenue , its patent expiration created a wave of lower-priced alternatives , significantly impacting its market share . While specific businesses may seek to capitalize on male sexual dysfunction,